Skip to main content

Amgen Inc.

corporate_fare Company Profile

Amgen Inc.

AMGN·NASDAQ·Life Sciences·CIK 0000318154

Amgen Inc. discovers, develops, manufactures, and delivers innovative medicines to address challenging diseases, focusing on areas with high unmet medical needs. The company, which helped launch the biotechnology industry over 45 years ago, is now one of the world's leading independent biotechnology companies. Amgen has a presence in approximately 100 countries worldwide. The company operates in one operating segment: human therapeutics. Amgen was incorporated in California in 1980 and became a Delaware corporation in 1987. Regarding significant developments, in August 2025, the FDA broadened the approved use of Repatha to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C), removing the previous requirement of a prior cardiovascular disease diagnosis. In November 2025, detailed results from the Phase 3 VESALIUS-CV clinical trial for Repatha were announced. This trial showed that Repatha, when added to statins or other LDL-C-lowering treatments, achieved statistically significant and clinically meaningful reductions in MACEs in high-risk adults without a prior heart attack or stroke. Repatha demonstrated a 25% relative reduction in the risk of a composite of coronary heart disease (CHD) death, heart attack, or ischemic stroke (3-P MACE), and a 19% reduction in a broader composite that also included any ischemia-driven arterial revascularization (4-P MACE). Repatha also reduced the risk of heart attack by 36%. In a lipid sub-study, the median achieved LDL-C was 45 mg/dL compared to 109 mg/dL in the placebo arm.

Amgen Inc. (NASDAQ:AMGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 54 items for AMGN at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Amgen Q2 Beat, Raised Guidance, and FDA Talks on TAVNEOS Drive Optimism
  • Amgen Q2 2026: Strong Beat and Raised Guidance, but TAVNEOS Withdrawal Threat and Tax Dispute Loom
  • Amgen Lifts Full-Year Outlook After Q2 Sales Smash Estimates
  • Amgen Tops Q2 Forecasts, Lifts Outlook; Pipeline Gains Offset by TAVNEOS Uncertainty
  • Amgen Q2 Earnings Crush Estimates, Raises 2026 Outlook on Drug Demand

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$36.75B
Net Income
$7.71B
Diluted EPS
$14.23
Op. Cash Flow
$9.96B
Free Cash Flow
$8.1B
Gross Profit
$24.71B
Operating Income
$9.08B
Cash & Equivalents
$9.13B
Total Debt
$54.6B
Debt / Equity
6.31×
Net Margin
21.0%
Shares Outstanding
538.8M sh
Source: 10-K · filed 2026-02-13 · accession 0000318154-26-000010
$438.5 +0.66% today
52-week range · as of 2026-11-03 $292.12 – $475.64
Market cap
$235.64B
Volume
4.9M (1.8× avg)
3-mo avg 2.7M
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AMGN - Filings & News (Page 2)

AMGN
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $410.82
Real-time Price: $438.50 info
Change: +$27.68 (+7%) info
Market Cap: $235.643B info
AMGN
Aug 04, 2026, 6:29 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $393.00
Real-time Price: $438.50 info
Change: +$45.50 (+12%) info
Market Cap: $235.643B info
AMGN
Aug 04, 2026, 4:10 PM EDT
Source: Binance News
Importance Score:
8
Price at Filing: $389.16
Real-time Price: $438.50 info
Change: +$49.34 (+13%) info
Market Cap: $235.643B info
AMGN
Aug 04, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $392.11
Real-time Price: $438.50 info
Change: +$46.39 (+12%) info
Market Cap: $235.643B info
AMGN
Aug 04, 2026, 4:02 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $392.46
Real-time Price: $438.50 info
Change: +$46.04 (+12%) info
Market Cap: $235.643B info
AMGN
Aug 04, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $391.77
Real-time Price: $438.50 info
Change: +$46.73 (+12%) info
Market Cap: $235.643B info
AMGN
Jul 31, 2026, 4:26 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $384.00
Real-time Price: $438.50 info
Change: +$54.50 (+14%) info
Market Cap: $235.643B info
AMGN
Jul 31, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $385.16
Real-time Price: $438.50 info
Change: +$53.34 (+14%) info
Market Cap: $235.643B info
AMGN
Jul 29, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $393.97
Real-time Price: $438.50 info
Change: +$44.53 (+11%) info
Market Cap: $235.643B info
AMGN
Jul 24, 2026, 8:13 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $373.15
Real-time Price: $438.50 info
Change: +$65.35 (+18%) info
Market Cap: $235.643B info
AMGN
Jul 06, 2026, 7:19 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $373.00
Real-time Price: $438.50 info
Change: +$65.50 (+18%) info
Market Cap: $235.643B info
AMGN
Jul 01, 2026, 4:45 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $361.33
Real-time Price: $438.50 info
Change: +$77.17 (+21%) info
Market Cap: $235.643B info
AMGN
Jun 22, 2026, 2:28 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $344.28
Real-time Price: $438.50 info
Change: +$94.23 (+27%) info
Market Cap: $235.643B info
AMGN
Jun 13, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $355.98
Real-time Price: $438.50 info
Change: +$82.52 (+23%) info
Market Cap: $235.643B info
AMGN
Jun 05, 2026, 7:30 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $348.84
Real-time Price: $438.50 info
Change: +$89.66 (+26%) info
Market Cap: $235.643B info
AMGN
Jun 01, 2026, 4:00 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $329.14
Real-time Price: $438.50 info
Change: +$109.37 (+33%) info
Market Cap: $235.643B info
AMGN
May 21, 2026, 6:24 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $330.90
Real-time Price: $438.50 info
Change: +$107.60 (+33%) info
Market Cap: $235.643B info
AMGN
May 19, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $330.75
Real-time Price: $438.50 info
Change: +$107.75 (+33%) info
Market Cap: $235.643B info
AMGN
May 15, 2026, 3:37 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $327.64
Real-time Price: $438.50 info
Change: +$110.86 (+34%) info
Market Cap: $235.643B info
AMGN
May 04, 2026, 9:02 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $328.60
Real-time Price: $438.50 info
Change: +$109.90 (+33%) info
Market Cap: $235.643B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets